FindTrial
Sign In

A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multicenter Trial Evaluating the Effects of Two Dosing Regimens of Nolasiban on Uterine Contractility and Endocrine Parameters

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-524896-22-00
Enrollment
120
Registered
2026-05-06
Start date
Unknown
Completion date
Unknown
Last updated
2026-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Women with an indication for IVF/ICSI

Brief summary

Change in uterine contractility index from Day 1 to Day 4 of treatment

Interventions

DRUGProduct

Sponsors

ReproNovo ApS
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Change in uterine contractility index from Day 1 to Day 4 of treatment—

Outcome results

None listed

Source: EU CTIS · Data processed: May 7, 2026